Based in Perth, Australia, Patrys, a publicly-listed company on the Australian Securities Exchange (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program.

Patrys’ deoxymab platform comprises novel cell-penetrating antibodies designed to target intracellular disease mechanisms, with a focus on immune-mediated inflammatory and other high-unmet-need indications. The platform builds on technology in-licensed from Yale University and is being progressed through a comprehensive preclinical development program.

Patrys’ CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive care, aged care and palliative care settings. The program is designed to leverage established safety and pharmacology data through the FDA 505(b)(2) regulatory pathway, offering a shorter and more predictable development timeline with clearly defined clinical and regulatory milestones.

Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation. The Company continues to advance both programs toward clinical and commercial outcomes and welcomes strategic partnership discussions across its portfolio.

Patrys Limited

Org chart

Teams

Offices